The pipeline for new treatments for Alzheimer's disease (AD) in the USA contains 
over 100 different agents, 80% of which can be categorized as disease-modifying 
therapies. The regulatory approval of the disease-modifying agent aducanumab has 
brought more attention to the complexity of the diagnosis, evaluation, and 
treatment of AD and the difficult decisions payers and policy makers will face 
over the next few years as innovation continues in this space. The value of AD 
treatment can vary widely according to the perspective of the analysis, sources 
of data, and methodological approach for the value assessment. This article 
focuses on AD-specific data gaps and measurement challenges and provides 
guidance for evidence generation to facilitate better value assessments for 
future AD treatments.